188 related articles for article (PubMed ID: 17129872)
1. OMICS and brain tumour biomarkers.
Petrik V; Loosemore A; Howe FA; Bell BA; Papadopoulos MC
Br J Neurosurg; 2006 Oct; 20(5):275-80. PubMed ID: 17129872
[TBL] [Abstract][Full Text] [Related]
2. OMICS-driven biomarker discovery in nutrition and health.
Kussmann M; Raymond F; Affolter M
J Biotechnol; 2006 Aug; 124(4):758-87. PubMed ID: 16600411
[TBL] [Abstract][Full Text] [Related]
3. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity.
Merrick BA; Bruno ME
Curr Opin Mol Ther; 2004 Dec; 6(6):600-7. PubMed ID: 15663324
[TBL] [Abstract][Full Text] [Related]
4. Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies.
Tzika AA; Astrakas L; Cao H; Mintzopoulos D; Andronesi OC; Mindrinos M; Zhang J; Rahme LG; Blekas KD; Likas AC; Galatsanos NP; Carroll RS; Black PM
Int J Mol Med; 2007 Aug; 20(2):199-208. PubMed ID: 17611638
[TBL] [Abstract][Full Text] [Related]
5. Proteomics analysis in lung cancer: challenges and opportunities.
Kikuchi T; Carbone DP
Respirology; 2007 Jan; 12(1):22-8. PubMed ID: 17207021
[TBL] [Abstract][Full Text] [Related]
6. Proteomics: new technologies and clinical applications.
Latterich M; Abramovitz M; Leyland-Jones B
Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
[TBL] [Abstract][Full Text] [Related]
7. Proteomic approaches for serum biomarker discovery in cancer.
Maurya P; Meleady P; Dowling P; Clynes M
Anticancer Res; 2007; 27(3A):1247-55. PubMed ID: 17593616
[TBL] [Abstract][Full Text] [Related]
8. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
9. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
Fayed N; Dávila J; Medrano J; Olmos S
Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
[TBL] [Abstract][Full Text] [Related]
10. From expert opinion to evidence-based: changes in the gold standard of primary brain tumour diagnosis.
Kros JM
J Pathol; 2007 Sep; 213(1):1-3. PubMed ID: 17593567
[TBL] [Abstract][Full Text] [Related]
11. Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software.
Wang QT; Li YZ; Liang YF; Hu CJ; Zhai YH; Zhao GF; Zhang J; Li N; Ni AP; Chen WM; Xu Y
Anat Rec (Hoboken); 2009 Apr; 292(4):604-10. PubMed ID: 19301277
[TBL] [Abstract][Full Text] [Related]
12. Integration of -omics data and networks for biomedical research with VANTED.
Klukas C; Schreiber F
J Integr Bioinform; 2010 Feb; 7(2):112. PubMed ID: 20134079
[TBL] [Abstract][Full Text] [Related]
13. High-dimensional biology to comprehend hepatocellular carcinoma.
Vivekanandan P; Singh OV
Expert Rev Proteomics; 2008 Feb; 5(1):45-60. PubMed ID: 18282123
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer diagnosis with complementary learning fuzzy neural network.
Tan TZ; Quek C; Ng GS; Razvi K
Artif Intell Med; 2008 Jul; 43(3):207-22. PubMed ID: 18541419
[TBL] [Abstract][Full Text] [Related]
15. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.
Ransohoff DF
J Clin Epidemiol; 2007 Dec; 60(12):1205-19. PubMed ID: 17998073
[TBL] [Abstract][Full Text] [Related]
16. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.
Miller LD; Liu ET
Breast Cancer Res; 2007; 9(2):206. PubMed ID: 17397520
[TBL] [Abstract][Full Text] [Related]
17. A combination of rough-based feature selection and RBF neural network for classification using gene expression data.
Chiang JH; Ho SH
IEEE Trans Nanobioscience; 2008 Mar; 7(1):91-9. PubMed ID: 18334459
[TBL] [Abstract][Full Text] [Related]
18. Astrocytoma derived short-term cell cultures retain molecular signatures characteristic of the tumour in situ.
Potter NE; Phipps K; Harkness W; Hayward R; Thompson D; Jacques TS; Harding B; Thomas DG; Rees J; Darling JL; Warr TJ
Exp Cell Res; 2009 Oct; 315(16):2835-46. PubMed ID: 19523942
[TBL] [Abstract][Full Text] [Related]
19. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
20. Protein arrays for biomarker discovery.
Reid JD; Parker CE; Borchers CH
Curr Opin Mol Ther; 2007 Jun; 9(3):216-21. PubMed ID: 17608019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
